These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 12185441)
1. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Sander A; Beiderlinden M; Schmid EN; Peters J Intensive Care Med; 2002 Aug; 28(8):1157-60. PubMed ID: 12185441 [TBL] [Abstract][Full Text] [Related]
2. Treatment of life-threatening multiresistant staphylococcal and enterococcal infections in patients with end-stage renal failure with quinupristin/dalfopristin: preliminary report. Schwenger V; Mündlein E; Dagrosa EE; Fahr AM; Zeier M; Mikus G; Andrassy K Infection; 2002 Oct; 30(5):257-61. PubMed ID: 12382082 [TBL] [Abstract][Full Text] [Related]
3. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system]. Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514 [TBL] [Abstract][Full Text] [Related]
4. Quinupristin/Dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Winston DJ; Emmanouilides C; Kroeber A; Hindler J; Bruckner DA; Territo MC; Busuttil RW Clin Infect Dis; 2000 May; 30(5):790-7. PubMed ID: 10817685 [TBL] [Abstract][Full Text] [Related]
5. Synercid plus vancomycin for the treatment of severe methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci infections: evaluation of 5 cases. Sgarabotto D; Cusinato R; Narne E; Scano F; Zignol M; Gambino A; Cattelan A; Meneghetti F; Cadrobbi P Scand J Infect Dis; 2002; 34(2):122-6. PubMed ID: 11928842 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Tverdek FP; Crank CW; Segreti J Crit Care Clin; 2008 Apr; 24(2):249-60, vii-viii. PubMed ID: 18361944 [TBL] [Abstract][Full Text] [Related]
7. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey. Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of quinupristin/dalfopristin versus vancomycin, alone or in combination with rifampicin, against methicillin-resistant Staphylococcus aureus in a rabbit arthritis model. Hamel A; Caillon J; Jacqueline C; Batard E; Potel G Int J Antimicrob Agents; 2008 Feb; 31(2):158-60. PubMed ID: 18006281 [TBL] [Abstract][Full Text] [Related]
18. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Raad I; Hachem R; Hanna H; Girgawy E; Rolston K; Whimbey E; Husni R; Bodey G Antimicrob Agents Chemother; 2001 Nov; 45(11):3202-4. PubMed ID: 11600379 [TBL] [Abstract][Full Text] [Related]
19. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Micek ST Clin Infect Dis; 2007 Sep; 45 Suppl 3():S184-90. PubMed ID: 17712745 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Martone WJ; Lamp KC Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]